Last reviewed · How we verify
Placebo、CAPOX
CAPOX is a chemotherapy regimen that combines capecitabine and oxaliplatin to treat cancer.
CAPOX is a chemotherapy regimen that combines capecitabine and oxaliplatin to treat cancer. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer.
At a glance
| Generic name | Placebo、CAPOX |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | chemotherapy regimen |
| Target | thymidylate synthase, DNA repair enzymes |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CAPOX works by inhibiting thymidylate synthase and DNA repair enzymes, leading to DNA damage and cell death in rapidly dividing cancer cells. Capecitabine is converted into 5-fluorouracil, which is then phosphorylated to form 5-fluorodeoxyuridylate, a potent inhibitor of thymidylate synthase. Oxaliplatin, on the other hand, forms platinum-DNA adducts, which interfere with DNA replication and transcription.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colon cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Neutropenia
Key clinical trials
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (PHASE3)
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) (PHASE3)
- A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). (PHASE3)
- ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma (PHASE3)
- Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma (PHASE3)
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (PHASE3)
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (PHASE3)
- Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |